Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.69 |
| ▸ | MEN1 | O00255 | 7/20 | 0.69 |
| ▸ | CNR1 | P21554 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | MYOC | Q99972 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA4 | P22748 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9357972 | 0.92 | HTT (0.60) | POLBHTTKMT2AMEN1CNR1 | |
| SCHEMBL27929224 | 0.91 | HTT (0.66) | POLBHTTKMT2AMEN1CNR1 | |
| SCHEMBL6907398 | 0.86 | POLB (0.72) | POLBHTTKMT2AMEN1CNR1 | |
| SCHEMBL11745025 | 0.86 | POLB (0.68) | POLBHTTKMT2AMEN1CNR1 | |
| SCHEMBL10805170 | 0.86 | POLB (0.68) | POLBHTTKMT2AMEN1CNR1 | |
| SCHEMBL14574144 | 0.86 | ACHE (0.62) | POLBHTTKMT2AMEN1CNR1 | |
| Hydrochloric Acid SCHEMBL326624 | 0.84 | POLB (0.66) | POLBHTTKMT2AMEN1CNR1 | |
| SCHEMBL27182713 | 0.84 | POLB (0.66) | POLBHTTKMT2AMEN1CNR1 | |
| SCHEMBL27923049 | 0.84 | POLB (0.70) | POLBHTTKMT2AMEN1CNR1 | |
| SCHEMBL21583073 | 0.84 | KDM4E (0.60) | POLBHTTKMT2AMEN1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103183682-B | C-10 carbamido substituted artemisinin derivative and preparation method and application thereof | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2015-10-14 | — | — | CN | disclosed |
| CN-103183682-A | C-10 carbamido substituted artemisinin derivative and preparation method and application thereof | UNIV SHENYANG PHARMACEUTICAL | 2013-07-03 | — | — | CN | disclosed |
| US-20070066615-A1 | Heterocyclic compounds | BAYER HEATHCARE AG (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20060287315-A1 | Pyrazinedicarboxamides and their use | BAYER HEALTHCARE AG (DE) | 2006-12-21 | — | — | US | disclosed |
| EP-0621962-A1 | FUNCTIONALIZED MEROCYANINE DYES AND POLYMERS INCORPORATING SUCH DYES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-11-02 | — | — | EP | disclosed |
| US-5256784-A | Merocyanine dyes | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-10-26 | — | — | US | disclosed |
| WO-1993015596-A2 | FUNCTIONALIZED MEROCYANINE DYES AND POLYMERS INCORPORATING SUCH DYES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287315-A1 | Pyrazinedicarboxamides and their use | PEPD, AADAC, PYCARD | POLB 3588/4885HTT 2939/4885KMT2A 1950/4885 |
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | PLK2, PLK4, PDXK | POLB 9/4885HTT 4331/4885KMT2A 849/4885 |
| US-20070066615-A1 | Heterocyclic compounds | F2, SERPINC1, TFPI | POLB 1495/4885HTT 182/4885KMT2A 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.